# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Dordaviprone is an oral, first-in-class small molecule imipridone that selectively binds to the G-protein coupled dopamine rece...
Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by...
https://twitter.com/DrTedros/status/1778423967105139108
HC Wainwright & Co. analyst Edward White reiterates Chimerix (NASDAQ:CMRX) with a Buy and maintains $11 price target.
Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 1...
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...
https://www.reuters.com/business/healthcare-pharmaceuticals/who-very-worried-about-spread-mpox-drc-2023-12-08/?taid=65734f21df0...